Industry News
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by increasing production of proteins involved in interferon- α and interferon- γ pathways • Demonstrated statistically significant increases in survival when combined with carboplatin and everolimus (mTOR inhibitor) Excerpt from the Press Release: SAN…
Read More
Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccinesStudy suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ — A Duke University-led study published in bioRxiv showed that Vaxart,…
Read More
Program delivered on smartphone is based on core principles of cognitive behavioral therapy, with focus on behavioral activation Trial results demonstrate clinically meaningful reduction in depression symptoms Completing SparkRx as recommended results in statistically significant reduction in symptoms compared to control Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Today, Limbix, a prescription digital therapeutic company developing…
Read More
Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios Excerpt from the Press Release: MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to…
Read More
Excerpt from the Press Release In the race to find new ways to prevent and treat COVID-19, OICR-supported researchers have launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. The trial involves IMM-101, a preparation of safe, heat-killed bacteria that broadly stimulates the…
Read More
This issuance expands global protection for Kinetic River’s technologies aimed at expanding the power of flow cytometry Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ — Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies…
Read More
Excerpt from the Press Release: LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone…
Read More
New research published today in Science Advances describes precise mechanism of how Alu reverse transcription occurs from RNA to cDNA, and its subsequent triggering of inflammasome activation and consequent cell death in Geographic Atrophy (GA) – the most severe form of dry age-related macular degeneration. Research shows Alu RNA/cDNA reverse transcription confined to rim of…
Read More
Excerpt from the Press Release: MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) — Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351…
Read More